Nxera Pharma Co., Ltd. is a technology-driven biopharmaceutical company engaged in the research, development, and commercialization of specialty medicines. The company operates a single pharmaceutical business segment, focusing on addressing unmet medical needs in Japan, South Korea, and the broader Asia-Pacific region. Its core activities span the entire drug development lifecycle, from early-stage discovery and translational medicine to clinical trials and sales. Key subsidiaries include Nxera Pharma UK Limited, which handles GPCR structural analysis and lead compound generation using the proprietary NxStaR technology, and Nexera Pharma Japan Co., Ltd., which manages clinical development and sales in Japan. Nxera Pharma Korea Co., Ltd. oversees operations in South Korea. The company utilizes the NxWave platform for rational structure-based drug design targeting GPCRs. Established in 1990 as Sosei Co. Ltd., the group has evolved to include nine consolidated subsidiaries, with a strategic focus on in-house development, in-licensed assets, and partnerships for global commercialization while retaining rights for the Asia-Pacific market.

Summarised from the annual report, fiscal year ended Dec 2025

Industry Biotechnology Homepage nxera.life
Sector Healthcare IR page investors.nxera.life
Tags
specialty pharmaceuticals, gpcr, structure-based drug design, translational medicine, clinical development, biopharmaceutical r&d, Nxera Pharma UK Limited, Nexera Pharma Japan Co. Ltd., Nxera Pharma Korea Co. Ltd., NxStaR, NxWave, Heptares Therapeutics Zurich AG, Sosei Co. Ltd.
Press page investors.nxera.life/news

Metrics

Valuation  
Market cap ¥ 111.046B
Market cap (USD) $ 694.044M
P/E -20.02
PEG —
P/BV 1.73
P/S 3.13
P/OCF -41.62
P/FCF -33.72
Dividend yield —
Turnover / mcap —
Returns  
ROE -19.3%
ROI -15.3%
ROIC -7.7%
Profit margin -42.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -64.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 29.615B 28.835B 12.766B 15.569B 17.712B 8.842B 9.726B 2.872B 18.901B 18.901B 8.151B 2.069B 1.958B
Net profit -12.53B -4.838B -7.193B 382M 1.017B 1.479B 1.432B -5.977B 9.311B 9.311B -1.432B -122M -646M
Free cash flow -3.293B -9.255B -6.124B 9.649B 6.894B 4.567B 3.161B — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.004K 1.048K 1.426K 2.138K 1.904K 1.8K 2.171K — 10.88K 2.719K 2.747K 2.642K 3.28K
Price performance 12m -0.04 -0.27 -0.33 0.12 0.06 -0.17 — — 2.96 -0.01 0.04 -0.19 —

Filed figures

Figure Mar 2017 Mar 2018 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (JPY) — — 987M 1.92B 939M 2.14B 2.46B 5.06B 6.7B 7.73B
↳ YoY growth +94.9% -51.2% +127.7% +15.2% +105.7% +32.2% +15.5%
↳ 5y CAGR +38.7% +28.3% +52.4%
Borrowings, non-current (JPY) — — — — — — — 32.7B 26.9B 21.1B
Lease liabilities (JPY) — — — 1.88B 1.83B 1.83B 1.75B 4.82B 4.38B 4.39B
Cash and deposits (JPY) 13.9B 28.3B 18.8B 15.4B 40B 60.1B 66.6B 49.1B 32.3B 20.4B
Intangible assets (JPY) — — 14.4B 13B 11.8B 9.12B 8.58B 52.3B 51.9B 49.2B
Net debt (borrowings + leases - cash) (JPY) — — — — — — — -11.6B -1B 5.14B
Cash flow detail
Operating cash flow (JPY) 12.9B -2.17B -4B 3.44B 4.67B 7.1B 9.95B -5.27B -7.72B -2.67B
Purchases of property, plant and equipment (JPY) — — -1.81B -271M -92M -193M -277M -804M -526M -448M
Purchases of intangible assets (JPY) — — -352M -9M -13M -8M -26M -47M -1.01B -177M
Change in receivables (cash effect) (JPY) — — -243M -880M 909M -799M -210M 1.32B -742M -1.04B
Change in inventories (cash effect) (JPY) — — — — — — -32M 1.91B -5.94B -2.46B
Change in payables (cash effect) (JPY) — — 210M -258M 61M -184M 315M 1.55B -487M 2.97B
Interest paid (cash effect) (JPY) — — -99M -103M -60M -157M -171M -241M -435M -531M
Income taxes paid (cash effect) (JPY) — — -23M -93M -168M -296M -262M -1.39B -428M -241M
Share-based compensation (JPY) — — 421M 384M 626M 713M 700M 870M 1.4B 1.95B
Operating cash flow before change in receivables (JPY) — — -3.75B 4.32B 3.76B 7.89B 10.2B -6.59B -6.98B -1.63B
Free cash flow (OCF - PPE - intangibles) (JPY) — — -6.15B 3.16B 4.57B 6.89B 9.65B -6.12B -9.26B -3.29B
Income detail
Research and development expense (JPY) — — 5.38B 4.29B 3.79B 5.93B 7.45B 10.1B 11.8B 14.5B
↳ 5y CAGR +13.4% +22.5% +30.7%
Total comprehensive income (JPY) — — -7.62B 2.37B 661M 5.62B -255M -1.12B 319M -9.47B
Comprehensive income to owners (JPY) 5.28B -1.23B -7.62B 2.37B 661M 5.62B -255M -1.12B 319M -9.47B
Reported Jun 23, 2017 Jun 22, 2018 Mar 25, 2020 Mar 24, 2021 Mar 24, 2021 Mar 24, 2022 Mar 27, 2024 Mar 27, 2024 Mar 26, 2025 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nxera Pharma Announces Vamorolone Selected for South Korea’s Accelerated Reimbursement Pilot Program for Rare Disease Treatments • Vamorolone is one of five treatments selected for the rare disease reimbursement pilot program. • The program aims to shorten the National Health Insurance listing process to within 100 days. • Together with GIFT priority review, the accelerated reimbursement pathway could enable a South Korean launch in 2027, earlier than the previously announced target of 2028. Tokyo, Japan and Cambridge, UK, 6 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that vamorolone, a treatment for Duchenne muscular dystrophy (DMD), has been selected for the South Korean government’s Accelerated Reimbursement Pilot Program for Rare Disease Treatments. Vamorolone is one of five treatments selected for the pilot program. The program aims to improve access to rare disease treatments by streamlining the National Health Insurance (NHI) listing process following regulatory approval, with a target duration of no more than 100 days. It combines simplified pre-listing assessment and pricing procedures with post-listing reassessment based on real-world evidence (RWE), supporting earlier patient access alongside continued evaluation of therapeutic value. On 22 October 2026, Nxera announced the submission of a Marketing Authorization Application (MAA) for vamorolone to South Korea’s Ministry of Food and Drug Safety (MFDS). Vamorolone has already received Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation in South Korea and is currently under regulatory review. Taking into account priority review under GIFT, Nxera is targeting regulatory approval in the third quarter of 2027. The accelerated reimbursement pathway, together with GIFT priority review, could enable Nxera to bring forward the commercial launch of vamorolone in South Korea to 2027 from the previously announced target of 2028. The Company will work closely with the relevant South Korean authorities to advance regulatory approval, reimbursement and product supply preparations, with the aim of launching vamorolone concurrently with its NHI listing. The timing of launch will depend on the progress of regulatory review and reimbursement procedures. Following NHI listing and commercial launch, real-world data (RWD) from Korean patients is expected to be collected through a patient registry established by the Health Insurance Review & Assessment Service (HIRA). The resulting RWE is expected to support reassessment of vamorolone’s longterm clinical outcomes and therapeutic value.

Mr. MinBok Lee, President and Representative Director of Nxera Pharma Korea, commented: " Selection for this pilot program is an important step towards giving patients with DMD and their families in South Korea earlier access to a new treatment option. Together with the GIFT priority review pathway, it could help us shorten the time from regulatory review to reimbursed availability of vamorolone. We are grateful to Santhera Pharmaceuticals for the scientific evidence and close collaboration that have supported this progress. We will continue to work with the Korean authorities and our partners to secure regulatory approval, complete reimbursement procedures and establish a reliable supply of vamorolone for patients.” About South Korea’s Accelerated Reimbursement Pilot Program for Rare Disease Treatments Introduced by the South Korean government in 2026, the pilot program is designed to improve timely access to medicines for patients with serious rare diseases and to evaluate the feasibility and effectiveness of a new accelerated reimbursement system. Predefined contractual terms replace separate negotiations on drug prices and total pharmaceutical expenditure under the conventional listing process. Prices are set with reference to 90% of the lowest adjusted price across eight reference countries (A8). Reimbursement prices and coverage conditions may subsequently be revised following reassessment of real-world clinical outcomes. The A8 reference countries are the United States, United Kingdom, Germany, France, Italy, Switzerland, Japan and Canada. About Duchenne Muscular Dystrophy Duchenne muscular dystrophy (DMD) is a rare inherited X-chromosome-linked disease, which almost exclusively affects males. DMD is characterized by inflammation which is present at birth or shortly thereafter. Inflammation leads to fibrosis of muscle and is clinically manifested by progressive muscle degeneration and weakness. Major milestones in the disease are the loss of ambulation, the loss of selffeeding, the start of assisted ventilation, and the development of cardiomyopathy. DMD typically reduces life expectancy to before the fourth decade due to respiratory and/or cardiac failure. About vamorolone Vamorolone is a dissociative corticosteroid approved for the treatment of Duchenne muscular dystrophy (DMD). It binds selectively to the glucocorticoid receptor and triggers anti-inflammatory activity through inhibition of NF‑κB-mediated gene transcription, while inducing reduced transactivation of other genes [1]. Vamorolone is not a substrate for 11‑β-hydroxysteroid dehydrogenase (11β-HSD) enzymes, which are involved in the local amplification of glucocorticoid activity in tissues and have been implicated in corticosteroid-associated toxicity [2,3]. This pharmacological profile is the basis for its classification as a dissociative corticosteroid, designed to preserve anti-inflammatory efficacy while reducing the systemic effects associated with long-term conventional corticosteroid therapy [1–3]. In the pivotal Phase 2b VISION-DMD study, vamorolone met its primary endpoint, demonstrating a statistically significant improvement in Time to Stand (TTSTAND) velocity versus placebo at 24 weeks (p = 0.002) [4]. The most commonly reported adverse reactions were cushingoid features, vomiting, weight increase, increased appetite, and irritability; most were mild to moderate in severity [1]. Long-term data from up to eight years of vamorolone treatment were presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in March 2026[5,6]. In propensity-matched analyses, vamorolone demonstrated durable efficacy comparable to standard-of-care corticosteroids and a differentiated safety profile: a lower incidence of vertebral fractures versus deflazacort-treated cohorts (8.1% vs 41.9%; p = 0.0082) [5]; maintained normal growth trajectory with a mean height advantage of 12.17 cm versus conventional corticosteroids (p < 0.0001) [5,6], and a lower incidence of cataracts versus deflazacort (p = 0.015), with no observed cases of glaucoma [5]. 2 of 3

References

[1] AGAMREE® (vamorolone) Summary of Product Characteristics. European Medicines Agency; authorised 14 December 2023. [2] Heier CR, Damsker JM, Yu Q, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. Life Sci Alliance. 2019;2(1): e201800186. [3] Reeves EKM, Hoffman EP, Nagaraju K, et al. VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem. 2013; 21(8): 2241–2249. [4] Dang UJ, Damsker JM, Guglieri M, et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy (VISIONDMD). Neurology. 2024;102(5): e208112. [5] Guglieri M, et al. Long-term impact of vamorolone on bone health compared to standard of care glucocorticoids in boys with Duchenne muscular dystrophy. Poster 62S, MDA Clinical & Scientific Conference 2026. [6] McDonald CM, et al. Comparative analysis of long-term effectiveness of vamorolone versus standard of care glucocorticoid treatment in boys with Duchenne muscular dystrophy. Poster 23S, MDA Clinical & Scientific Conference 2026.

–END– About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, newgeneration commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

Prompts

Nxera Pharma Co., Ltd. (ticker 4565), listed in Japan.

ETFs Holding Nxera Pharma Co., Ltd.

ETF Weight in ETF Shares Market value As of
DFIS 0.06% 285,700 $ 3.195M Nov 12, 2026
DXIV 0.01% 1,400 $ 15.655K Nov 12, 2026
DFSI 0.00% 2,700 $ 30.191K Nov 12, 2026
DFAX 0.00% 8,400 $ 93.929K Nov 12, 2026
DFAI 0.00% 11,709 $ 130.93K Nov 12, 2026